The presence of anti-Ro52/tripartite motif 21 (Trim21) autoantibodies has been associated with a distinctive clinical profile and has gained value as a prognostic marker in idiopathic inflammatory myopathies (IIM). The aim of the present work was to analyse Ro52/Trim21 expression in different subsets of peripheral blood mononuclear cells (PBMCs) of patients with IIM, as well as the ubiquitination profile and its association with proinflammatory cytokine production. We included 18 patients with recentonset IIM and 18 age-and gender-matched healthy donors. PBMCs were isolated and different subsets (CD4
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Summary
The presence of anti-Ro52/tripartite motif 21 (Trim21) autoantibodies has been associated with a distinctive clinical profile and has gained value as a prognostic marker in idiopathic inflammatory myopathies (IIM). The aim of the present work was to analyse Ro52/Trim21 expression in different subsets of peripheral blood mononuclear cells (PBMCs) of patients with IIM, as well as the ubiquitination profile and its association with proinflammatory cytokine production. We included 18 patients with recentonset IIM and 18 age-and gender-matched healthy donors. PBMCs were isolated and different subsets (CD4
1 ) were purified by magnetic selection. The expression of Ro52/Trim21 in different PBMC subsets of patients with IIM and healthy donors was analysed by Western blot. We assessed the presence of myositis-specific and associated autoantibodies by enzyme-linked immunosorbent assay (ELISA). Cytokine levels were measured by cytometric bead array. Patients with IIM showed decreased protein expression of Ro52/Trim21 in comparison to healthy controls in PBMC (0Á97 6 0Á60 versus 1Á84 6 0Á92, P 5 0Á016), CD4
Introduction
The superfamily of tripartite motif (TRIM)-containing proteins comprises more than 70 members in the human genome and has been related to diverse biological processes, such as tumorigenesis, transcriptional regulation, posttranslational modifications and viral neutralization [1, 2] . TRIM protein structures includes multiple domains: at the N-terminal region they display common domains, including a RING (Really Interesting New Gene) finger with ubiquitin ligase activity (E3) and one or two B-box domains, as well as a coiled coil domain. Furthermore, at the C-terminal region, the PRYSPRY domain is the one that provides target specificity. Particularly, the RING finger and the PRYSPRY domains are related closely to their biological functions [3] .
Moreover, Trim21 is considered a cytosolic Fc receptor, with broad antibody specificity and the highest affinity in humans (0Á6 nM) [4] . As an Fc receptor, it binds to antibodies bound to pathogens that enter the cytosol (virus or bacteria), acting as damage-associated molecular patterns (DAMP) signals, and mediates antibody-dependent cellular neutralization (ADIN), with concurrent induction of inflammatory signalling cascades, that culminate in efficient pathogen elimination [5, 6] .
Trim21 is able to regulate innate immunity through interaction with PRR (pattern recognition receptors), such as Toll-like receptor (TLR)-3 and cytosolic DNA sensors, as DDX41 [7] . Trim21 also stimulates the transcription factor pathways of nuclear factor jB (NF-jB), activator protein 1 (AP)-1, interferon regulatory factor 3 (IRF3), 5, 7 and 8, mediated by its ligase activity, catalyzing the formation of K63-linked ubiquitin chains, which induces the production of diverse proinflammatory cytokines and chemokines [interleukin (IL)-6, IL-12p40, tumour necrosis factor (TNF)-a, type I interferon (IFN), CXCL10, CCL2 and CCL4]. This process has been shown in diverse cellular lineages, such as mouse embryonic fibroblasts (MEFs) and macrophages [5, 8] . It has been shown in diverse in-vitro and in-vivo systems that type I IFN is able to induce Trim21 expression [9, 10] . Furthermore, Trim21
-/-null mice develop systemic autoimmunity similar to lupus (hypergammaglobulinaemia, DNA autoantibodies and kidney disease) dependent upon proinflammatory cytokine (IL-6, TNF-a, IFN-a, IFN-b, IL-12/IL-23p40 and IL-17) production, mediated by the ubiquitination status of the transcription factors IRF3, IRF5 and IRF8. In this model, systemic autoimmunity developed only after tissue injury induced by the ear tags, with similar frequency in the haploinsufficient mice, which suggests that even a partial loss of function of Trim21 is able to confer enhanced tissue inflammation and systemic autoimmunity [11] .
Trim21 has E3 ubiquitin ligase activity and is involved closely in its biological functions. Indeed, ubiquitination is a post-translational modification that involves a series of sequential enzymatic reactions that culminate in the conjugation of one or more ubiquitin molecules to a protein substrate. The ubiquitin ligases are the ones that confer target specificity [12] . Also, the lysine residue where the ubiquitin is anchored is able to determine the fate of the target. Most of the K48 substrates are directed towards proteasomal degradation, whereas K63 ubiquitination has been related to regulation of the substrate function [13] . Trim21 has been shown to regulate diverse substrates by K48 and K63 ubiquitin conjugation. Moreover, ubiqutination has been shown to be able to regulate immune responses, particularly tolerance induction in other systemic autoimmune diseases, such as SLE [14] . However, neither the ubiquitination profile nor the specific lysine residues that are involved have been addressed in IIM.
Trim21, which is also known widely as Ro52, is an autoantigen in systemic autoimmune diseases, such as SLE, Sj€ ogren's syndrome and, more recently, systemic sclerosis and idiopathic inflammatory myopathies (IIM) [15] . Anti-Ro52 autoantibodies have been associated with myositis in other autoimmune diseases, such as Sj€ ogren's syndrome and systemic sclerosis [16] . Particularly, in IIM, anti-Ro52 autoantibodies have been detected in approximately 30% of patients; they might be the only specificity found in 14% of them, and overlap frequently with anti-synthetase autoantibodies [17] . Moreover, potential pathogenic and prognostic roles have been suggested for anti-Ro52 autoantibodies in IIM patients in terms of mortality and its association with interstitial lung disease (77Á7%) and cancer development (19Á4%) [10, 18] . Despite their high prevalence in myositis patients the expression of Trim21, as well as its biological role linked to its ubiquitin ligase activity, have not been addressed fully, particularly in different peripheral blood subsets, such as lymphocytes and monocytes, which constitutes the main aim of the present study.
Materials and methods

Patients and healthy controls
We included 18 patients with recent-onset diagnosis (< 1 month) of IIM according to Bohan and Peter's criteria, seen at the Instituto Nacional de Ciencias M edicas y Nutrici on Salvador Zubir an, a tertiary care centre in Mexico City from March 2013 to April 2014. Twelve patients with diagnosis of dermatomyositis (DM), three with polymyositis (PM) and three with anti-synthetase syndrome (AAS), as well as age-and gender-matched healthy donors, were included in the study. All patients with IIM had active disease at the time of the inclusion. Patients with juvenile dermatomyositis, other forms of myopathies or autoimmune disease, infection or pregnancy were excluded. The study was approved by the Institutional Ethics Committee. All subjects signed informed consent prior to the inclusion in the study.
Cell isolation and cytokine production
Peripheral blood mononuclear cells (PBMCs) were obtained from IIM patients and healthy donors by densitygradient centrifugation (Lymphoprep, Oslo, Norway 
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Autoantibody quantification
We assessed the presence of the following myositis-specific and associated autoantibodies (MSAs, MEAs): Ro-52, Jo-1, OJ, EJ, PL-7, PL12, Ku, SRP, Mi-2, PM/Scl-75 and PM/Scl-100 by immunoblot (Euroline Autoimmune Inflammmatory Myopathies 16 Ag; Euroimmun AG, Luebeck, Germany).
Statistical analysis
Results are expressed as the mean 6 standard deviation, unless noted otherwise. Differences between groups were analysed using the independent-sample Student's t-test; Pvalues less than 0Á05 were considered statistically significant; SPSS software (version 21.0) was used for statistical analyses. 
Results
Baseline demographic and clinical characteristics
Patients with IIM display diminished expression of Ro52/Trim21 in different subsets of PBMC
Patients with IIM showed decreased protein expression of Ro52/TRIM21 in comparison to healthy controls in different PBMC subsets, as follows: total PBMC (0Á9713 6 0Á6037 versus 1Á8493 6 0Á9274, P 5 0Á016), CD4 1 lymphocytes (0Á7973 6 0Á5404 versus 2Á4134 6 0Á7868, P 5 0Á017) and monocytes (0Á8751 6 0Á3586 versus 1Á8908 6 0Á2092, P < 0Á001). CD8 1 lymphocytes from IIM patients also showed a trend towards lower Ro52/TRIM21 expression (0Á9025 6 0Á7081 versus 1Á6102 6 0Á5404, P 5 0Á133). We did not find significant differences among IIM groups (see Fig 1) . Interestingly, no significant association was detected between the levels of expression of Trim21 and the titres of anti-Ro52 antibodies (P 5 0Á80).
Patients with IIM show a differential polyubiquitination profile via Lys48 predominantly in CD4 1 T lymphocytes
Because we found a deficient expression of the E3 ligase Ro52/Trim21, we decided to assess further the ubiquitination profile on different subsets of PBMCs from IIM patients and healthy donors.
There was a decrease in the global ubiquitination profile in mononuclear cells, monocytes and T CD4 1 lymphocytes from IIM patients compared to healthy controls. Next, we assessed if the lower ubiquitination profiles were dependent upon poly-ubiquitination. Indeed, we found a predominantly lower K48 poly-ubiquitination profile, particularly in CD4 1 T cells from patients with IIM in comparison to healthy controls (Fig. 2) . K63 poly-ubiquitination did not
show any differences among PBMCs subsets between IIM samples and healthy controls (data not shown).
Deficiency of Ro52/Trim21 in CD4 1 T lymphocytes and monocytes from patients with IIM is associated with a proinflammatory cytokine response upon stimulation As detailed in the Methods, CD4 1 lymphocytes were either left unstimulated (RPMI) or stimulated with plate-bound anti-CD3 antibody and soluble anti-CD28 antibody for 48 h. Similarly, CD14 1 monocytes were incubated with RPMI or LPS for 48 h. Afterwards, the supernatants were collected and IFN-a was measured by ELISA and the other cytokines by CBA. After stimulation, we found increased synthesis of IL-17A (80Á22 6 28Á57 versus 14Á7 6 5Á47pg/ ml, P 5 0Á017) and TNF-a (2325Á1 6 405Á14 versus 1055Á62 6 235Á21, P 5 0Á005) in the supernatants of CD4
1
T cells from IIM patients in comparison to healthy controls. Similarly, after LPS stimulation, increased synthesis of IL-6 (8441Á2 6 1801Á03 versus 1996Á6 6 650Á58 pg/ml, P 5 0Á003) and IFN-a (85Á27 6 13Á78 versus 13Á3 6 0Á87 pg/ml, P 5 0Á002) was found in monocytes from patients with IIM versus healthy donors (Fig. 3) . We found no differences in unstimulated samples from either CD4 1 T lymphocytes or monocytes between the two groups (data not shown). The other cytokines assessed showed no significant differences between IIM patients and healthy donors, in both unstimulated and stimulated cultures.
Discussion
The presence of autoantibodies towards Ro52/Trim21 are a hallmark in diverse systemic autoimmune diseases; particularly in IIM patients, these autoantibodies are associated with a clinical and serological profile and are suggested as prognostic markers associated with a decreased cumulative survival during a 10-year follow-up [19] . Despite their key clinical role, the expression and functional relevance of the Ro52/Trim21 autoantigen had not been addressed fully in these patients. Our data suggest that IIM patients, particularly those with DM, which was the most prevalent type of IIM included, are characterized by a deficiency of Trim21 in different peripheral blood subsets. Furthermore, this was related to a deficient global ubiquitination profile mediated by K48 poly-ubiquitin species in lymphocytes and monocytes, and these defects were associated with a proinflammatory cytokine response. In the present work, anti-Ro52/Trim21 antibodies were detected in 27Á7% of patients, being the most prevalent autoantibody found, which is similar to what has been reported by others [15, 20, 21] . Our data show that patients with IIM display lower Ro52/Trim21 expression in peripheral total PBMCs, CD4
1 lymphocytes and monocytes, in comparison to healthy controls. These data correlate with the findings by Espinosa et al. [11] , who showed the development of systemic autoimmunity in the null Trim21 -/-mice. Even though the presence of myositis was not assessed in that model, mice developed other features of autoimmunity. However, this autoimmune phenotype has been a matter of controversy, as it was not found by another group [22] , although different strategies for generation, as well as other environmental factors (tissue injury) might explain the differences. Trim21 has been shown to be an interferon-inducible protein.
In particular, it has been shown that IRF1 and 2 promote its expression, and IRF4 and 8 repress the ISRE promoter [23] . These data suggest that the IRF1 : IRF4 ratio might be a key element that regulates Trim21 expression. Hence, we could hypothesize that patients with IIM could present a higher IRF4 expression that keeps the Trim21 promoter repressed, an effect that cannot be overcome by IRF1, which is currently under evaluation by our group. Until the present, there has been no assessment of IRF expression in IIM patients. Recently, Fletcher et al. [24] found that Trim21 is able to be regulated by sequential Ube2W and Ube2N-mediated mono-and poly-ubiquitination and the subsequent proteasomedependent de-ubiquitination mediated by Poh1. Therefore, the diminished Trim21 expression could be related to abnormalities in this ubiquitination-de-ubiquitination system. Espinosa et al. [25] have shown, by ubiquitination assays, that anti-Ro52 antibodies inhibit the E3 ligase activity of Ro52/Trim21 by sterically blocking the E2/E3 interaction. However, there has not been an association between the levels of anti-Ro52 antibodies and Ro52/Trim21 expression, which is in agreement with our findings.
We also found that the deficiency of Ro52/Trim21 was associated with a diminished poly-ubiquitination profile, which was more striking in CD4
1 T lymphocytes of IIM versus healthy controls. Moreover, this was mediated mainly by K48 poly-ubiquitin species. In this regard, it has been shown that K48 poly-ubiquitination is required for IjBa degradation and NF-jB activation mediated by Trim21 [26] . This lower K48 ubiquitination profile might have functional implications, in which less substrates will be directed towards proteasomal degradation, which could have profound impact on signal transduction, particularly in specific subsets, such as CD4 1 T lymphocytes. Besides, it can serve as a counter-regulatory mechanism in case anchored Ub-63 Ub would be the predominant form, as the absence of the Ub-
48
Ub conjugation prevents proteasomal recruitment and then prevents abnormal Trim21-mediated signalling. It is not surprising that this defect is expressed differentially in CD4
1 T lymphocytes, as the action of Trim21 seems to differ among various peripheral cells, such as embryonic fibroblasts and monocytes, as shown by Yoshimi et al. [22] . As we found that Ro52/Trim21 was deficient in IIM patients and that this related to a particular ubiquitin profile in a cell-specific manner, we decided to assess if Ro52/Trim21 deficiency had any impact in effector functions, such as the production of proinflammatory cytokines. Indeed, we found increased production of TNF-a and IL-17 from CD4 1 T lymphocytes, as well as IL-6 and IFN-a from monocytes. Our data agree with what has been found in both murine models in particular peripheral subsets. In the work by Espinosa et al. [11] , they also found increased IL-17 production by CD3 1 cells in the context of Trim21 deficiency. Moreover, in IIM patients, increased Th17 cells have also been found previously by our group and others [27] [28] [29] . Trim21 has been acknowledged as a master regulator of NF-jB signalling, mainly through the modulation of IjBa proteasomal degradation. In this regard, in Trim21 -/-MEFs display an increased NF-jB promoter activity, which was associated with increased production of IL-6 and TNFa, in agreement with our findings in monocytes and lymphocytes, respectively. Furthermore, it has been shown that Tax-activated IKKb is mono-ubiquitinated by Trim21, which triggers its translocation to autophagosomes for degradation [30] . Hence, in Trim21-deficient cells, this mono-ubiquitinated IKKb is decreased, as well as the autophagosomes that promote enhanced NF-jB signalling. IRF3, 7 and 8 have all been shown to be Trim21 substrates [9, [31] [32] [33] which explains the link between Trim21 and type I IFNs. In particular, Trim21-mediated IRF3 ubiquitination regulates the type I IFN promoter negatively, specifically after TLR stimulation. In fact, blocking Trim21 by shRNA is associated with an increased TLR-3-mediated type I IFN and regulated upon activation normal T cell expressed and secreted (RANTES) production [32] , which is in agreement with our results of higher type I IFN levels after stimulation with LPS. Trim21 also acts as a precision autophagy receptor, binding to active (dimerized) IRF3 and inducing a complex with ULK1 and mATG8s, promoting its degradation. Thus, IIM patients display Trim21 deficiency and increased type I IFN after LPS stimulation potentially secondary to decreased precision autophagy.
Furthermore, we assessed Trim21 expression by Western blot; however in the near future, when commercially available flow cytometry validated antibodies for Trim21 exist, it could represent an easily available way to identify a subset of patients with Trim21 expression as a biomarker of a proinflammatory cytokine profile in subjects with idiopathic inflammatory myopathies.
In summary, patients with IIM display a deficient Trim21 expression, which is associated with a lower K48 poly-ubiquitination profile in a cell-specific manner (CD4 1 T lymphocytes and monocytes) and related to a proinflammatory cytokine response, characterized by increased IL-6, IL-17, TNF-a and type I IFN production. This response could be related to the effect of Trim21 as a master regulator for NF-jB and IRF signalling pathways in IIM. Further insights into the function of this protein will have profound implications for the understanding of its role in IIM.
